| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Pyrimidine-4-carboxylic acid does not have a defined pharmacological target as it is a synthetic intermediate. The compound has been shown to have anticancer activity and anti-inflammatory properties, which may be due to its ability to inhibit prostaglandin synthesis. It serves as a key building block in the synthesis of antiviral and anticancer agents.
|
|---|---|
| ln Vitro |
One synthetic intermediate that can be employed in the manufacture of drugs is pyrimidine-4-carboxylic acid.
In vitro studies have demonstrated that Pyrimidine-4-carboxylic acid has anticancer activity and inhibits the growth of tumor cells. It also has anti-inflammatory properties, which may be due to its ability to inhibit prostaglandin synthesis. The compound is used as a building block in pharmaceutical development. |
| ln Vivo |
No specific in vivo pharmacological activity data have been documented for Pyrimidine-4-carboxylic acid as a therapeutic agent. The compound is used as a synthetic intermediate in pharmaceutical development. Its derivatives may be evaluated in animal models depending on the therapeutic area.
|
| Enzyme Assay |
For non-cellular assays, Pyrimidine-4-carboxylic acid is characterized by standard analytical techniques including HPLC, NMR, and mass spectrometry to confirm identity and purity. The compound can be evaluated as a substrate in various organic reactions. Typical protocols involve dissolving the compound in appropriate solvents. Purity: 97%.
|
| Cell Assay |
For in vitro cell-based studies, Pyrimidine-4-carboxylic acid can be used to assess anticancer activity. Cells are cultured under standard conditions and treated with the compound to evaluate effects on tumor cell growth inhibition. The compound is typically dissolved in appropriate solvents and diluted in cell culture medium. Appropriate controls should be included.
|
| Animal Protocol |
For in vivo animal studies, Pyrimidine-4-carboxylic acid can be formulated using standard injection vehicles. The compound is a solid at room temperature. Dosing solutions should be freshly prepared and administered according to specific protocols with appropriate control groups. Storage: keep in dark place, sealed in dry, room temperature.
|
| ADME/Pharmacokinetics |
Pyrimidine-4-carboxylic acid has a molecular weight of 124.10 and molecular formula C5H4N2O2. It has a melting point of 229.8-231.9°C and density of 1.403±0.06 g/cm³. Storage: keep in dark place, sealed in dry, room temperature. Purity: 97%.
|
| Toxicity/Toxicokinetics |
Pyrimidine-4-carboxylic acid is for research use only and not for human consumption. Standard laboratory safety practices should be followed when handling this chemical. Appropriate personal protective equipment including gloves and safety glasses should be worn. Specific LD50 values and detailed toxicological profiles have not been extensively reported.
|
| Additional Infomation |
Pyrimidine-4-carboxylic acid (CAS 31462-59-6) is also known as 4-pyrimidinecarboxylic acid. It is a synthetic intermediate useful for pharmaceutical synthesis, particularly in the development of antiviral and anticancer agents. The compound has anticancer activity and anti-inflammatory properties. It is used as a building block in organic synthesis.
|
| Molecular Formula |
C5H4N2O2
|
|---|---|
| Molecular Weight |
124.10
|
| Exact Mass |
124.027
|
| CAS # |
31462-59-6
|
| PubChem CID |
169306
|
| Appearance |
Off-white to gray solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
318.7±15.0 °C at 760 mmHg
|
| Melting Point |
229.8-231.9ºC
|
| Flash Point |
146.5±20.4 °C
|
| Vapour Pressure |
0.0±0.7 mmHg at 25°C
|
| Index of Refraction |
1.579
|
| LogP |
0.47
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
9
|
| Complexity |
116
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
OC(C1C=CN=CN=1)=O
|
| InChi Key |
YPOXGDJGKBXRFP-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C5H4N2O2/c8-5(9)4-1-2-6-3-7-4/h1-3H,(H,8,9)
|
| Chemical Name |
pyrimidine-4-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 8.0580 mL | 40.2901 mL | 80.5802 mL | |
| 5 mM | 1.6116 mL | 8.0580 mL | 16.1160 mL | |
| 10 mM | 0.8058 mL | 4.0290 mL | 8.0580 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
